Valuation: Ocugen, Inc.

Market Cap 277M 247M 226M 206M 388M 26.18B 398M 2.71B 1.08B 13.87B 1.04B 1.02B 43.75B P/E 2026 *
-3.16x
P/E 2027 * -3.02x
Enterprise Value 210M 188M 172M 156M 294M 19.89B 302M 2.06B 824M 10.53B 790M 773M 33.23B EV / Sales 2026 *
42.5x
EV / Sales 2027 * 50.4x
Free-Float
98.56%
Yield 2026 *
-
Yield 2027 * -
1 day-6.63%
1 week+9.72%
Current month+16.19%
1 month-21.49%
3 months-36.21%
6 months-45.20%
Current year-39.52%
1 week 0.7
Extreme 0.7036
0.93
1 month 0.69
Extreme 0.6909
1.05
Current year 0.69
Extreme 0.6909
2.72
1 year 0.69
Extreme 0.6909
2.72
3 years 0.35
Extreme 0.351
2.72
5 years 0.34
Extreme 0.345
10.4
10 years 0.17
Extreme 0.17
18.77
Manager TitleAgeSince
Chief Executive Officer 62 26/09/2019
Director of Finance/CFO - 08/02/2026
Chief Operating Officer - 28/02/2026
Director TitleAgeSince
Director/Board Member 71 04/06/2025
Chairman 62 26/09/2019
Director/Board Member 52 04/06/2025
Date Insider Type Main position Quantity % Market Cap. Importance
09/10/26 Sell

Chief Executive Officer

-525,991 0.1551%
09/09/26 Sell

Chief Executive Officer

-525,991 0.1551%
01/04/26 Exercice

Director

388,268 0.1184%
Change 5-day change 1-year change 3-year change Capi.($)
-6.63%+9.72%-42.09%+112.08% 297M
+3.80%+8.10%+63.78%+77.70% 66.87B
+0.07%+1.39%+12.75%+75.17% 57.2B
+1.63%+4.93%+24.89%+104.31% 56.55B
+0.41%-3.70%+26.06%+34.32% 43.47B
+2.51%+4.22%+20.49%+110.71% 42.95B
-11.04%-6.63%+199.38%+701.67% 42.8B
+7.50%+13.58%+29.07%+64.46% 34.01B
+1.59%-4.04%+97.66%+79.95% 32.11B
-2.79%+6.61%+35.49%-5.35% 25.27B
Average -0.28%+4.02%+46.75%+135.50% 40.15B
Weighted average by Cap. +0.60%+3.43%+54.68%+140.29%

Financials

2026 *2027 *
Net sales 4.96M 4.42M 4.04M 3.68M 6.94M 468M 7.12M 48.54M 19.41M 248M 18.61M 18.21M 783M 5.5M 4.9M 4.48M 4.08M 7.7M 520M 7.9M 53.86M 21.54M 275M 20.64M 20.2M 869M
Net income -86.69M -77.25M -70.66M -64.35M -121M -8.19B -125M -849M -339M -4.34B -325M -318M -13.69B -94.65M -84.34M -77.15M -70.26M -132M -8.94B -136M -927M -371M -4.74B -355M -348M -14.95B
Net Debt -66.6M -59.35M -54.28M -49.44M -93.19M -6.29B -95.7M -652M -261M -3.33B -250M -245M -10.52B -
Projected Income Statement - Annual - Ocugen, Inc.
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
116
Date Price Change Volume
05/11/26 US$0.8165 -6.63% 7,153,701
04/11/26 US$0.8745 +17.35% 8,813,279
03/11/26 US$0.7452 +2.83% 4,981,406
02/11/26 US$0.7247 +3.13% 5,712,759
30/10/26 US$0.7027 -5.58% 5,424,046
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Ocugen, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.8165USD
Average target price
12.17USD
Spread / Average Target
+1,390.10%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ocugen, Inc.
  1. Stock Market
  2. Stocks
  3. OCGN Stock